Profile data is unavailable for this security.
About the company
Oxurion NV, formerly known as ThromboGenics NV, is a Belgium-based biopharmaceutical company, which focuses on the development and commercialization of ophthalmic medicines. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. Oxurion partners with Alcon (Novartis) for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns, which was launched in the United Kingdom and Germany. In addition, it also explores anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of ophthalmic and oncology indications. The Company is active domestically, as well as operates through offices located in the United States and Ireland.
- Revenue in EUR (TTM)2.00k
- Net income in EUR1.96m
- Incorporated2006
- Employees11.00
- LocationOxurion NVGaston Geenslaan 1LEUVEN (LOUVAIN) 3001BelgiumBEL
- Phone+32 16751310
- Fax+32 16751311
- Websitehttps://www.oxurion.com
Mergers & acquisitions
| Acquired company | OXUR:BRU since announced | Transaction value |
|---|---|---|
| Undisclosed Contract Research Organization | -72.00% | 1.21m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| bioXXmed AG | 3.49k | -996.91k | 323.52k | 1.00 | -- | 1.02 | -- | 92.70 | -5.23 | -5.23 | 0.0176 | 1.17 | 0.006 | -- | 0.0572 | 3,490.00 | -170.22 | -39.81 | -206.00 | -40.13 | -- | -- | -28,564.76 | -25,207.92 | -- | -6.95 | 0.00 | -- | -79.94 | -37.36 | 95.24 | -- | -- | -- |
| Oxurion NV | 2.00k | 1.96m | 420.59k | 11.00 | 0.0098 | -- | 0.2075 | 210.30 | 0.6137 | 0.6137 | 0.0006 | -3.76 | 0.0004 | -- | 0.0015 | 181.82 | 41.10 | -101.52 | -- | -249.96 | -650.00 | 53.85 | 97,950.00 | -2,672.68 | -- | -- | -- | -- | -98.86 | -76.22 | 100.63 | -- | -- | -- |
| PCI Biotech Holding ASA | 417.33k | -1.83m | 463.54k | 7.00 | -- | 0.4161 | -- | 1.11 | -0.5502 | -0.5502 | 0.1256 | 0.3353 | 0.1676 | -- | 0.896 | 669,714.30 | -73.44 | -41.44 | -92.22 | -46.61 | -- | -- | -438.10 | -897.91 | -- | -- | 0.022 | -- | 125.25 | -6.43 | 19.19 | -- | -- | -- |
| MediGene AG | -100.00bn | -100.00bn | 494.27k | 87.00 | -- | 0.0249 | -- | -- | -- | -- | -- | 1.33 | -- | -- | -- | -- | -- | -22.31 | -- | -25.28 | -- | 90.15 | -- | -123.17 | -- | -- | 0.1146 | -- | -80.69 | -4.89 | -94.20 | -- | -8.12 | -- |
| Paion AG | -100.00bn | -100.00bn | 642.03k | 64.00 | -- | -- | -- | -- | -- | -- | -- | -0.4074 | -- | -- | -- | -- | -- | -24.86 | -- | -34.32 | -- | -- | -- | -52.40 | 0.5078 | -- | 1.17 | -- | 366.42 | 41.74 | 97.34 | -- | 129.37 | -- |
| Shortwave Life Sciences PLC | -4.95k | -406.17k | 686.39k | 2.00 | -- | 0.2424 | -- | -- | -0.0085 | -0.0085 | -0.0001 | 0.0454 | -0.0014 | -- | -- | -2,150.00 | -11.85 | -- | -12.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -19.39 | -- | 76.00 | -- | -- | -- |
| Epigenomics AG | 4.00k | -2.76m | 841.87k | 3.00 | -- | -- | -- | 210.47 | -3.14 | -3.14 | 0.0046 | 0.00 | 0.0003 | -- | -- | 2,000.00 | -23.10 | -55.09 | -23.17 | -61.61 | -2,300.00 | -0.2095 | -69,025.00 | -473.65 | -- | -- | 1.00 | -- | -100.00 | -- | 24.90 | -- | -- | -- |
| GeNeuro SA | 0.00 | -14.76m | 916.64k | 19.00 | -- | -- | -- | -- | -0.594 | -0.594 | 0.00 | -0.5548 | 0.00 | -- | -- | 0.00 | -165.51 | -96.43 | -356.72 | -185.61 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -20.96 | -- | -20.13 | -- |
| Respiratorius AB (publ) | 0.00 | -646.04k | 947.22k | -- | -- | 0.3331 | -- | -- | -1.15 | -1.15 | 0.00 | 3.87 | 0.00 | -- | -- | -- | -22.10 | -- | -22.91 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 8.10 | -- | -- | -- |
| Stayble Therapeutics AB | 0.00 | -643.71k | 1.07m | 2.00 | -- | 1.66 | -- | -- | -0.1227 | -0.1227 | 0.00 | 0.1076 | 0.00 | -- | -- | -- | -77.50 | -74.45 | -89.43 | -84.74 | -- | -- | -- | -- | -- | -3,463.50 | 0.1094 | -- | -- | -- | 44.21 | -- | -- | -- |
| IntegraGen SA | 6.69m | -1.55m | 1.21m | 39.00 | -- | 3.41 | -- | 0.1804 | -0.2338 | -0.2338 | 1.01 | 0.0526 | 1.36 | 8.98 | 4.92 | 171,592.60 | -31.48 | -1.90 | -115.71 | -4.51 | 59.50 | 64.12 | -23.12 | -1.44 | 0.9581 | -- | 0.5447 | -- | -30.62 | 0.9904 | -49.22 | -- | -- | -- |
| Novakand Pharma AB | 0.00 | -4.39m | 1.34m | 5.00 | -- | 0.9589 | -- | -- | -0.3897 | -0.3897 | 0.00 | 0.1243 | 0.00 | -- | -- | 0.00 | -112.94 | -58.37 | -122.10 | -66.37 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -5.98 | -- | -- | -- |
| Fluicell AB | 557.67k | -774.17k | 1.44m | 11.00 | -- | 1.42 | -- | 2.59 | -6.06 | -6.06 | 4.37 | 7.94 | 0.2729 | -2.23 | 7.04 | 545,636.40 | -37.89 | -81.30 | -54.89 | -120.68 | 218.79 | 135.50 | -138.82 | -549.48 | 0.6019 | -- | -- | -- | 222.86 | 5.31 | 46.28 | -- | 92.14 | -- |
